Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants

Study identifier:ALXN1920-HV-101

ClinicalTrials.gov identifier:NCT05751642

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Subcutaneously and Intravenously Administered ALXN1920 in Healthy Adult Participants

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

-

Sex

All

Actual Enrollment

48

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 24 Apr 2023
Primary Completion Date: 27 Oct 2023
Study Completion Date: 04 Dec 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Basic Science

Verification:

Verified 01 Jan 2024 by Alexion Pharmaceuticals, Inc.

Sponsors

Alexion Pharmaceuticals, Inc.

Collaborators

-

Inclusion and exclusion criteria